<DOC>
	<DOCNO>NCT00121615</DOCNO>
	<brief_summary>The objective study describe safety , tolerability , efficacy long-term administration etanercept adult psoriasis complete etanercept psoriasis study 20030115 20030117 , Canada , continue long-term extension . Subjects 20030115 study follow 24 month begin Oct. 2004 . Subjects 20030117 study follow 12 month begin mid 2005 .</brief_summary>
	<brief_title>Study Etanercept Treatment Psoriasis Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects complete study 20030115 20030117 qualify enroll study ( provide meet inclusion/exclusion criterion ) . Heterosexually active men woman childbearing potential must agree use medically acceptable form contraception throughout study . Subject designee must ability selfinject investigational product . Subject must capable understand give write voluntary informed consent . Negative serum pregnancy test less equal 14 day prior first dose investigational product female subject ( except surgically sterile least 5 year postmenopausal ) Active guttate , erythrodermic , pustular psoriasis time baseline visit Any adverse event infection time baseline visit time previous etanercept psoriasis study , opinion Amgen Investigator , would preclude participation study Presence serious infection less equal 30 day prior baseline visit Evidence skin condition baseline visit ( e.g. , eczema ) would interfere evaluation effect investigational product psoriasis Previous receipt antiTNF agent ( ) etanercept Receipt investigational product ( ) , etanercept , less equal 30 day prior first dose investigational product study Receipt antiCD4 diphtheria IL2 fusion protein less equal 24 week prior first dose investigational product study Psoralen ultraviolet A ( PUVA ) light therapy less equal 14 day prior first dose investigational product study Ultraviolet A ( UVA ) light therapy less equal 14 day prior first dose investigational product study Ultraviolet B ( UVB ) light therapy less equal 14 day prior first dose investigational product study Receipt systemic psoriasis therapy oral parenteral corticosteroid less equal 14 day prior first dose investigational product study Pregnant breastfeeding female Significant concurrent medical condition prior enrollment , include : uncontrolled hypertension ( define systolic blood pressure measurement great 180 mm Hg untreated diastolic blood pressure great 110 mm Hg ) ; myocardial infarction less equal 52 week prior baseline visit ; unstable angina pectoris ; uncompensated congestive heart failure ; severe pulmonary disease require hospitalization supplemental oxygen therapy ; diagnosis multiple sclerosis demyelinate disease ; insulindependent diabetes mellitus ; history cancer ( insitu cervical cancer resect cutaneous basal cell squamous cell carcinoma ) less equal 5 year prior administration first dose investigational product ; open cutaneous ulcer ; know human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) hepatitis C virus ( HCV ) positive ; condition might cause study detrimental subject , judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Clinical Trials</keyword>
</DOC>